2,242 Trial Deaths, Few Rules: India Aims for Regulatory Reform
By Randy Osborne
Monday, March 18, 2013
India's Drug and Cosmetics Act purports to keep clinical trials kosher under something called Schedule Y, but the law which has not been amended since 2005 lacks rules for mandatory practice and does not specify what recourse trial participants have when things go wrong.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.